The authors’ aim was to evaluate the tumor volume and growth rate of neurofibromatosis type 2 (NF2)–associated vestibular schwannomas (VSs) and the clinical factors or type of mutations before and after surgery in children and adults younger than 25 years at the time of diagnosis.
A total of 579 volumetric measurements were performed in 46 operated tumors in 28 NF2 patients, using thin-slice (< 3 mm) T1-weighted contrast-enhanced MRI. The follow-up period ranged from 21 to 167 months (mean 75 months). Growth rate was calculated using a multilinear regression model. Mutation analysis of the NF2 gene was performed in 25 patients.
Surgery significantly (p = 0.013) slowed the VS growth rate from 0.69 ± 1.30 cm3/yr to 0.23 ± 0.42 cm3/yr. Factors significantly associated with a higher growth rate of VSs were increasing patient age (p < 0.0005), tumor volume (p = 0.006), tumor size (p = 0.001), and constitutional truncating mutations in the NF2 gene (p = 0.018). VS growth rates tended to be higher in patients with spinal ependymomas and in right-sided tumors and lower in the presence of peripheral schwannomas; however, no statistical significance was achieved.
Decompression of the internal auditory canal with various degrees of tumor resection decreases the postoperative tumor growth rate in children and young adults with NF2-associated VS. Patients with potential risk factors for accelerated growth (e.g., large volume, truncating mutations) and with increasing age should be monitored more closely before and after surgery.
ABBREVIATIONSAEP = auditory evoked potential; IAC = internal auditory canal; NF2 = neurofibromatosis type 2; VS = vestibular schwannoma.
AntinheimoJHaapasaloHSeppäläMSainioMCarpenOJääskeläinenJ: Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol54:776–7821995
AntinheimoJ, HaapasaloH, SeppäläM, SainioM, CarpenO, JääskeläinenJ: Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. 54:776–782, 199510.1097/00005072-199511000-000047595650)| false
BonneNAboukaisRBaronciniMHochartALeblondPBrolyF: Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation. Childs Nerv Syst32:2403–24132016
EvansDGTruemanLWallaceACollinsSStrachanT: Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet35:450–4551998
EvansDG, TruemanL, WallaceA, CollinsS, StrachanT: Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. 35:450–455, 1998964328410.1136/jmg.35.6.450)| false
IannellaGde VincentiisMDi GioiaCCarlettiRPasquarielloBMannoA: Subtotal resection of vestibular schwannoma: evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation. J Int Med Res45:1061–10732017
IannellaG, de VincentiisM, Di GioiaC, CarlettiR, PasquarielloB, MannoA, : Subtotal resection of vestibular schwannoma: evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation. 45:1061–1073, 20172844749410.1177/0300060516686873)| false
KanzakiJ, TosM, SannaM, MoffatDA, MonsellEM, BerlinerKI: New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. 24:642–649, 200310.1097/00129492-200307000-0001912851559)| false
LiH, HaoSY, WangL, LiD, WuZ, ZhangLW, : Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2. 157:1983–1990, 201510.1007/s00701-015-2542-126287269)| false
ParryDMEldridgeRKaiser-KupferMIBouzasEAPikusAPatronasN: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet52:450–4611994
ParryDMMacCollinMMKaiser-KupferMIPulaskiKNicholsonHSBolestaM: Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet59:529–5391996
PeyreMGoutagnySBahABernardeschiDLarroqueBSterkersO: Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery72:907–9142013
PeyreM, GoutagnyS, ImbeaudS, Bozorg-GrayeliA, FelceM, SterkersO, : Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. 13:1125–1132, 20112179888710.1093/neuonc/nor101)| false
SaitoKKatoMSusakiNNagataniTNagasakaTYoshidaJ: Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol22:30–342003
SaitoK, KatoM, SusakiN, NagataniT, NagasakaT, YoshidaJ: Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. 22:30–34, 200312617191)| false
SamiiMMatthiesCTatagibaM: Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery40:696–7061997
SamiiM, MatthiesC, TatagibaM: Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. 40:696–706, 199710.1097/00006123-199704000-000079092842)| false